Churg-Strauss syndrome medical therapy: Difference between revisions
(Created page with "__NOTOC__ {{Churg-Strauss syndrome}} {{CMG}} ==Overview== ==Medical Therapy== Treatment for Churg-Strauss syndrome includes glucocorticoids such as prednisone at a dose ...") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Churg-Strauss syndrome}} | {{Churg-Strauss syndrome}} | ||
{{CMG}} | {{CMG}} | ||
Revision as of 19:40, 10 June 2016
|
Churg-Strauss syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Churg-Strauss syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Churg-Strauss syndrome medical therapy |
|
Risk calculators and risk factors for Churg-Strauss syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Treatment for Churg-Strauss syndrome includes glucocorticoids such as prednisone at a dose of 0.5-1.5 mg/kg per day x 6-12 weeks and other immunosupressive drugs such as azathioprine and cyclophosphamide. In many cases the disease can be put into a type of chemical remission through drug therapy, but the disease is chronic and life long.
A systematic review conducted in 2007 indicated that all patients should be treated with high-dose steroids, but that in patients with an FFS of 1 or higher cyclophosphamide pulse therapy should be commenced, with 12 pulses leading to less relapses than 6. Remission can be maintained with a less toxic drug, such as azathioprine or methotrexate.[1]
The erythrocyte sedimentation rate (ESR) and eosinophil count can be followed to gauge the response to therapy. Late relapses are uncommon and refractory disease may require Cyclophosphamide, Azathioprine, intravenous immunoglobulin (IVIG) and plasmapheresis.
References
- ↑ Bosch X, Guilabert A, Espinosa G, Mirapeix E (2007). "Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review". JAMA. 298 (6): 655–69. doi:10.1001/jama.298.6.655. PMID 17684188.